Immutep Announces Improving Results from Stage I of Phase II TACTI-002 Study
- Three complete responses (complete disappearance of all lesions) reported: two in 2nd line head and neck squamous cell carcinoma (HNSCC) and one in 1st line non-small cell lung cancer (NSCLC)
- Five responses in patients (both indications) with negative (< 1%) or moderate PD-L1 expression where pembrolizumab monotherapy does not work well
- Median Progression Free Survival (PFS) of 4.3 months in HNSCC patients and 47% progression free at 6 months in this very aggressive late stage disease
- PFS continues to improve in 1st line NSCLC patients with median PFS of 11.8 months and patients with responses have durable ones